# MEDICINOVA, INC. (MNOV) · Edgar & Edgarette company card

> Medicinova (MNOV) saw revenue fall 59.0% in FY2025 to $0 million, operating margin -3242% against a -3.8% median for pharmaceutical preparations, equity 91.2% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1226616 · fiscal year ended 2025-12-31 · 4 audited years read · [page](https://www.pops4.com/boards/company/MNOV) · [JSON](https://www.pops4.com/boards/company/MNOV.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $409,657 |
| Revenue growth, 1 year | -59.0% |
| Revenue growth per year | -5.0% |
| Operating margin | -3242.5% (prior year -990.0%) |
| Net margin | -2928.8% |
| Operating cash flow | −$10M |
| Capital spending | $2,899 |
| Free cash flow | −$10M |
| Cash | $31M |
| Long-term debt | — |
| Total assets | $46M |
| Total equity | $42M |
| Equity ÷ assets | 91.2% |
| Return on equity | -28.9% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -18.54 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative (-$9.8M in FY2025); operating loss: a margin of -3242.5% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $410K (FY2025). Experience: revenue down 59.0% on the year, down 5.0% a year over 13 years; operating margin -3242.5%, down from -990.0%. Soundness: equity 91.2% of assets, return on equity -28.9%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $182K and $326K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -3242.5% against a -3.8% median; growth -59.0% against 13.7%.

Range logged 2026-09-20, receipt 293da70218c2cb01, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-08-19 ([filing](https://www.sec.gov/Archives/edgar/data/1226616/000119312526356146/0001193125-26-356146-index.htm))

## Recent filings

- 8-K · filed 2026-09-28 · 1.01 Entry into a Material Definitive Agreement · [filing](https://www.sec.gov/Archives/edgar/data/1226616/000119312526405318/0001193125-26-405318-index.htm)
- 8-K · filed 2026-09-02 · 1.02 Termination of a Material Definitive Agreement · [filing](https://www.sec.gov/Archives/edgar/data/1226616/000119312526379348/0001193125-26-379348-index.htm)
- 8-K · filed 2026-08-19 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1226616/000119312526356146/0001193125-26-356146-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1226616/000119312526349323/0001193125-26-349323-index.htm)
- 8-K · filed 2026-06-24 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1226616/000119312526281171/0001193125-26-281171-index.htm)
- 10-Q · filed 2026-05-14 · [filing](https://www.sec.gov/Archives/edgar/data/1226616/000119312526224066/0001193125-26-224066-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001226616.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1226616

## Cite

POPS4, Edgar & Edgarette: MEDICINOVA, INC. (MNOV) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/MNOV. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.